Nitroxoline upregulates low-density lipoprotein receptors expression, enhances lipid metabolism, and reduces hepatic steatosis and atherosclerosis in Apoe−/− mice

Aug 20, 2025Biochimica et biophysica acta. Molecular basis of disease

Nitroxoline increases cholesterol receptor levels, improves fat processing, and reduces liver fat and artery plaque in mice lacking Apoe

AI simplified

mRNA Technology on OpenScience ↗PubMed ↗DOI ↗

Abstract

Nitroxoline significantly upregulated LDLR mRNA and protein expression, enhancing LDL uptake.

LDLRs are crucial for maintaining cholesterol levels, and their dysregulation is linked to conditions like atherosclerosis.
Nitroxoline was identified as a candidate for modulating LDLR through screening of FDA-approved drugs.
In Huh7 cells, nitroxoline promoted LDLR expression via the activation of specific gene pathways.
In mice, nitroxoline reduced total cholesterol, triglycerides, and LDL cholesterol levels without affecting HDL cholesterol.
Histological analyses indicated significant reductions in liver fat accumulation and fibrosis, as well as reduced atherosclerotic plaque formation.

AI simplified

Low-density lipoprotein receptors (LDLRs) play a critical role in maintaining cholesterol homeostasis. Dysregulation of lipid metabolism contributes to atherosclerosis and steatohepatitis. This study investigated the effects of nitroxoline on LDLR expression and its protective role in lipid dysregulation, hepatic steatosis, and atherosclerosis. Through comprehensive screening of FDA-approved clinical drugs, nitroxoline was identified as a promising candidate for modulating LDLR. Functional validation in Huh7 cells using quantitative reverse transcription polymerase chain reaction, western blotting, flow cytometry, and RNA-seq analysis showed that nitroxoline significantly upregulated LDLR mRNA and protein expression, enhancing LDL uptake and binding capacity. Mechanistically, nitroxoline promoted SREBF2 expression via PPP2CA suppression and stabilized LDLR mRNA through AMPK- and JNK-dependent repression of the RNA-binding proteins, notably HNRNPD. Transcriptomic profiling revealed increased expression of genes related to cholesterol homeostasis and decreased expression of genes involved in triglyceride biosynthesis, including GPAT, AGPAT, and PNPLA3. In Apoemice, nitroxoline reduced serum levels of total cholesterol, triglycerides, and LDL-C without affecting HDLC. Histological analyses demonstrated significant reductions in hepatic steatosis, fibrosis, and stellate cell activation, along with a modest attenuation of atherosclerotic plaque formation in the aortic root. These molecular and phenotypic effects were consistent with improved lipid clearance and hepatocellular protection. These findings suggest that nitroxoline exerts dual actions by upregulating LDLR expression and improving hepatic lipid metabolism. Given its established clinical safety and oral bioavailability, nitroxoline may offer repurposing potential as a therapeutic agent for treating lipid-related metabolic disorders and preventing atherosclerotic cardiovascular disease. -/-

Full Text

Full text is available at the source.

View full text (XML) ↗View full text ↗

Nitroxoline upregulates low-density lipoprotein receptors expression, enhances lipid metabolism, and reduces hepatic steatosis and atherosclerosis in Apoe−/− mice

Abstract

Full Text

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief

Abstract

Full Text

Related papers

You found one interesting study. We’ll send the next 7.

what lands in your inbox each week:

Recent issues from the mrna technology brief